Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: A meta-analysis

International Journal of Clinical Practice

Volumn 66, Issue 4, 2012, Pages 399-408

  Lin, T ^a   Wang, C ^a   Cai, X Z ^a   Zhao, X ^a   Shi, M M ^a   Ying, Z M ^a   Yuan, F Z ^a   Guo, C ^a   Yan, Shi Gui ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; PLACEBO;

BIBLIOGRAPHIC DATABASE; BONE DENSITY; BONE MASS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HAZARD ASSESSMENT; HIP; HUMAN; INFECTION; LUMBAR SPINE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY CONTROL; RADIUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG TOXICITY; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84862785572     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02806.x     Document Type: Review

References (30)

1. Melton LJ 3rd, Thamer M, Ray NF, et al., Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 16-23. (Pubitemid 27053607)
2. Weycker D, Macarios D, Edelsberg J, Oster G,. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645-52. (Pubitemid 44477625)
3. Takeyama S, Shinoda H,. [Pharmacological actions and pharmacokinetics of bisphosphonates]. Clin Calcium 2003; 13: 115-21.
4. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE,. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-74.
5. Bartl R, Gotte S, Hadji P, Hammerschmidt T,. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Dtsch Med Wochenschr 2006; 131: 1257-62. (Pubitemid 44173951)
6. Burgess TL, Qian Y, Kaufman S, et al., The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-38. (Pubitemid 29215717)
7. Yasuda H, Shima N, Nakagawa N, et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
8. Burkiewicz JS, Scarpace SL, Bruce SP,. Denosumab in osteoporosis and oncology. Ann Pharmacother 2009; 43: 1445-55.
9. Bone HG, Bolognese MA, Yuen CK, et al., Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-57. (Pubitemid 351831529)
10. von Keyserlingk C, Hopkins R, Anastasilakis A, et al., Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum 2011. PMID: 21616520. (accessed 19 July 2011).
11. Kong YY, Yoshida H, Sarosi I, et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
12. Wong BR, Josien R, Lee SY, et al., TRANCE [tumor necrosis factor (TNF)-related activation-induced cytokine], a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-80. (Pubitemid 28013694)
13. Schwartzman J, Yazici Y,. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 2390-1. Author reply.
14. Higgins JPT, Green S, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell, 2008.
15. McClung MR, Lewiecki EM, Cohen SB, et al., Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-31. (Pubitemid 43290920)
16. Atkins D, Best D, Briss PA, et al., Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
17. Brown JP, Prince RL, Deal C, et al., Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153-61.
18. Kendler DL, Roux C, Benhamou CL, et al., Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72-81.
19. Seeman E, Delmas PD, Hanley DA, et al., Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25: 1886-94.
20. Beck TJ, Lewiecki EM, Miller PD, et al., Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 2008; 11: 351-9.
21. Lewiecki EM, Miller PD, McClung MR, et al., Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22: 1832-41. (Pubitemid 351229299)
22. Miller PD, Bolognese MA, Lewiecki EM, et al., Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43: 222-9.
23. Qiu S, Rao DS, Palnitkar S, Parfitt AM,. Dependence of bone yield (volume of bone formed per unit of cement surface area) on resorption cavity size during osteonal remodeling in human rib: implications for osteoblast function and the pathogenesis of age-related bone loss. J Bone Miner Res 2010; 25: 423-30.
24. Seeman E, Delmas PD,. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-61.
25. Reid IR, Miller PD, Brown JP, et al., Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010; 25: 2256-65.
26. Baron R, Ferrari S, Russell RG,. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011; 48: 677-92.
27. Wray AE, Okita N, Ross AC,. Cortical and trabecular bone, bone mineral density, and resistance to ex vivo fracture are not altered in response to life-long vitamin A supplementation in aging rats. J Nutr 2011; 141: 660-6.
28. Russo CR, Lauretani F, Bartali B, Ferrucci L,. Trabecular and cortical bone in the assessment of vertebral fracture risk. Osteoporos Int 2002; 13: 266. (Pubitemid 34408196)
29. Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ,. RANKL inhibition: from mice to men (and women). Adv Exp Med Biol 2007; 602: 143-50.
30. Bekker PJ, Holloway DL, Rasmussen AS, et al., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-66. (Pubitemid 41110556)